French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)

Bernd Gänsbacher; Olivier Danos; George Dickson; Kris Thielemans; François Loic Cosset; Nicole Deglon; M. Sirac Dilber; Eithan Galun; David Klatzmann; Fulvio Mavilio; Naomi Taylor

doi:10.1002/jgm.364

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)

Bernd Gänsbacher, Olivier Danos, George Dickson, Kris Thielemans, François Loic Cosset, Nicole Deglon, M. Sirac Dilber, Eithan Galun, David Klatzmann, Fulvio Mavilio, Naomi Taylor

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Original language	English
Pages (from-to)	82-84
Number of pages	3
Journal	Journal of Gene Medicine
Volume	5
Issue number	1
DOIs	https://doi.org/10.1002/jgm.364
State	Published - Jan 2003

Access to Document

10.1002/jgm.364

Cite this

Gänsbacher, B., Danos, O., Dickson, G., Thielemans, K., Cosset, F. L., Deglon, N., Dilber, M. S., Galun, E., Klatzmann, D., Mavilio, F., & Taylor, N. (2003). French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT). Journal of Gene Medicine, 5(1), 82-84. https://doi.org/10.1002/jgm.364

@article{ce340547633e4c01986e1b06aeaa146e,

title = "French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)",

author = "Bernd G{\"a}nsbacher and Olivier Danos and George Dickson and Kris Thielemans and Cosset, {Fran{\c c}ois Loic} and Nicole Deglon and Dilber, {M. Sirac} and Eithan Galun and David Klatzmann and Fulvio Mavilio and Naomi Taylor",

year = "2003",

month = jan,

doi = "10.1002/jgm.364",

language = "אנגלית",

volume = "5",

pages = "82--84",

journal = "Journal of Gene Medicine",

issn = "1099-498X",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

Gänsbacher, B, Danos, O, Dickson, G, Thielemans, K, Cosset, FL, Deglon, N, Dilber, MS, Galun, E, Klatzmann, D, Mavilio, F & Taylor, N 2003, 'French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)', Journal of Gene Medicine, vol. 5, no. 1, pp. 82-84. https://doi.org/10.1002/jgm.364

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT). / Gänsbacher, Bernd; Danos, Olivier; Dickson, George et al.
In: Journal of Gene Medicine, Vol. 5, No. 1, 01.2003, p. 82-84.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)

AU - Gänsbacher, Bernd

AU - Danos, Olivier

AU - Dickson, George

AU - Thielemans, Kris

AU - Cosset, François Loic

AU - Deglon, Nicole

AU - Dilber, M. Sirac

AU - Galun, Eithan

AU - Klatzmann, David

AU - Mavilio, Fulvio

AU - Taylor, Naomi

PY - 2003/1

Y1 - 2003/1

UR - http://www.scopus.com/inward/record.url?scp=0037590036&partnerID=8YFLogxK

U2 - 10.1002/jgm.364

DO - 10.1002/jgm.364

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 12516054

AN - SCOPUS:0037590036

SN - 1099-498X

VL - 5

SP - 82

EP - 84

JO - Journal of Gene Medicine

JF - Journal of Gene Medicine

IS - 1

ER -

French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position statement from the European Society of Gene Therapy (ESGT)

Access to Document

Other files and links

Cite this